Literature DB >> 3491050

Role of interleukin-1 in the depression of liver drug metabolism by endotoxin.

P Ghezzi, B Saccardo, P Villa, V Rossi, M Bianchi, C A Dinarello.   

Abstract

Endotoxin-resistant C3H/HeJ mice were used to test the hypothesis that a macrophage product, possibly interleukin-1, might mediate the depression of liver cytochrome P-450-dependent drug metabolism in endotoxin-treated mice. Depression of liver drug metabolism by endotoxin was observed in normal mice (C3H/HeN) but not in C3H/HeJ mice. Serum transfer experiments demonstrated that a serum factor was responsible for the depression of liver drug metabolism. Experiments of passive transfer of peritoneal macrophages showed that this endotoxin-induced factor might be a macrophage product. In vitro experiments showed that endotoxin-stimulated monocytes produced a factor that depressed cytochrome P-450-dependent metabolism in cultured hepatocytes. Homogeneous human monocyte and recombinant interleukin-1 also depressed liver drug metabolism both in vivo and in vitro, suggesting that this macrophage product might be involved in the regulation of liver function by the immune system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491050      PMCID: PMC260246          DOI: 10.1128/iai.54.3.837-840.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Hepatic microsomal metabolism of drugs during pregnancy in the rat.

Authors:  M E Dean; B H Stock
Journal:  Drug Metab Dispos       Date:  1975 Sep-Oct       Impact factor: 3.922

2.  Prostacyclin synthesis induced in vascular cells by interleukin-1.

Authors:  V Rossi; F Breviario; P Ghezzi; E Dejana; A Mantovani
Journal:  Science       Date:  1985-07-12       Impact factor: 47.728

3.  Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells.

Authors:  J M Dayer; B de Rochemonteix; B Burrus; S Demczuk; C A Dinarello
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.

Authors:  P E Auron; A C Webb; L J Rosenwasser; S F Mucci; A Rich; S M Wolff; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

Review 5.  An update on human interleukin-1: from molecular biology to clinical relevance.

Authors:  C A Dinarello
Journal:  J Clin Immunol       Date:  1985-09       Impact factor: 8.317

6.  Role of reactive oxygen intermediates in the interferon-mediated depression of hepatic drug metabolism and protective effect of N-acetylcysteine in mice.

Authors:  P Ghezzi; M Bianchi; L Gianera; S Landolfo; M Salmona
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

7.  INTERFERON-LIKE VIRAL INHIBITOR IN RABBITS AFTER INTRAVENOUS ADMINISTRATION OF ENDOTOXIN.

Authors:  M HO
Journal:  Science       Date:  1964-12-11       Impact factor: 47.728

8.  Effects of three recombinant human leukocyte interferons on drug metabolism in mice.

Authors:  A Parkinson; J Lasker; M J Kramer; M T Huang; P E Thomas; D E Ryan; L M Reik; R L Norman; W Levin; A H Conney
Journal:  Drug Metab Dispos       Date:  1982 Nov-Dec       Impact factor: 3.922

9.  The role of interleukin 1 in acute phase serum amyloid A (SAA) and serum amyloid P (SAP) biosynthesis.

Authors:  J D Sipe; S N Vogel; M B Sztein; M Skinner; A S Cohen
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

10.  Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1.

Authors:  G Ramadori; J D Sipe; C A Dinarello; S B Mizel; H R Colten
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

View more
  26 in total

Review 1.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

3.  Regulation of cytochrome P450 4F11 by nuclear transcription factor-κB.

Authors:  Jordan C Bell; Henry W Strobel
Journal:  Drug Metab Dispos       Date:  2011-10-19       Impact factor: 3.922

4.  Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide.

Authors:  K Kitaichi; L Wang; K Takagi; M Iwase; E Shibata; M Nadai; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 5.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

6.  All-trans-retinoic acid distribution and metabolism in vitamin A-marginal rats.

Authors:  Christopher J Cifelli; A Catharine Ross
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-08       Impact factor: 4.052

7.  Repression of cytochrome P450 by cytokines: IL-1 beta counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes.

Authors:  J H Parmentier; P Kremers; L Ferrari; A M Batt; J E Gielen; G Siest
Journal:  Cell Biol Toxicol       Date:  1993 Jul-Sep       Impact factor: 6.691

8.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

9.  Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Authors:  J Schrenzel; F Cerruti; M Herrmann; T Leemann; E Weidekamm; R Portmann; B Hirschel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Coal dust alters beta-naphthoflavone-induced aryl hydrocarbon receptor nuclear translocation in alveolar type II cells.

Authors:  Mohamed M Ghanem; Lori A Battelli; Brandon F Law; Vincent Castranova; Michael L Kashon; Joginder Nath; Ann F Hubbs
Journal:  Part Fibre Toxicol       Date:  2009-08-03       Impact factor: 9.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.